Navigation Links
Research finds surgery outperforms drug therapy in treatment of benign prostatic hyperplasia

SAN FRANCISCO A 17-year-long community study looking at symptoms of enlarged prostate in over 2,000 men age 40 to 79 years suggests that surgery for benign prostatic hyperplasia (BPH) offers more relief from incontinence and obstruction symptoms than treatment from drug-based therapy, according to a new study by researchers at Mayo Clinic. The researchers presented their results today at the annual meeting of the American Urological Association.

Overall, results show:

  • Urinary incontinence was a common condition, coexisting with BPH/lower urinary tract symptoms.
  • In the community setting, patients with the highest symptom scores were most likely to receive surgical intervention.
  • Symptoms stabilized and did not get worse after treatment of all kinds.
  • Patients who underwent transurethral resection of the prostate (TURP) had the greatest decrease in both symptoms and incontinence compared to other treatment groups. Pre-TURP the incontinence rate was 64.5 percent and post-TURP it was 41.9 percent.


The findings provide large-sample, long-term data comparing the effectiveness of medical versus surgical treatments in a large, general population, as compared to small, select clinical populations of men. "Our data fills a gap in the research record that can be used by physicians and patients to evaluate management options," says Amy Krambeck, M.D., Mayo Clinic urologist and lead study investigator. "Because it's a large community-based study of more than 2,100 men, it includes the entire broad range of male health. This suggests the results are stronger in terms of being generalized and applied to other men."


BPH and lower urinary tract symptoms, such as frequent urge to urinate or leakage, are common. By age 60, an estimated 50 percent of all men suffer from enlarged prostate symptoms; by age 90, about 80 percent do. Multiple treatments exist. But data comparing drug therapy to surgery are lacking, making clinical decisions vulnerable to subjective factors.

About the Study

From 1990 through 2007, the study enrolled 2,184 healthy men, age 40-79, living in Olmsted County, Minn., All participants completed surveys every other year about their urinary symptoms and the treatments they received. From this information, the investigators examined urinary problems and incontinence before and after different types of treatment.

Results showed that of the 2,184 men:

  • 1,574 (72%) received no treatment for BPH symptoms.
  • 307 (14%) took alpha adrenergic receptor blockers (α-ARs).
  • 195 (9%) took the medication 5-alpha-reductase inhibitors (ARIs).
  • 23 (1%) received surgical laser vaporization.
  • 85 (4%) received surgical transurethral resection of the prostate (TURP).

Comments Dr. Krambeck: "After intervention, the greatest improvement in symptom score was seen in the TURP group, followed by laser vaporization, then the drugs, 5 alpha reductase inhibitors and alpha adrenergic receptor blockers. Only the surgical TURP group reported a decrease in incontinence pre-TURP the incontinence rate was 64.5 percent and post-TURP it was 41.9 percent." This reduction in incontinence rates is significant when compared to the increase in reported incontinence in the patients receiving both forms of medical therapy and no change in symptoms for patients receiving laser vaporization.


Contact: Traci Klein
Mayo Clinic

Related medicine news :

1. Researchers report no difference in breast cancer characteristics after oophorectomy
2. Vanderbilt researchers play major role in new center on electronic health information privacy
3. New research at the University of Leicester links shoplifting to your personality
4. OHSU joins forces with UO, Harvard to accelerate Fanconi anemia research
5. Pitt researchers discover gene mutation linked to lymphatic dysfunction
6. Researchers validate a new test for assessing childrens and teenagers fitness to prevent morbidity
7. Chef Charles Phillips of Nashville's 1808 Grille, Teams up with National Foundation for Cancer Research, Offering Gourmet Healthy Living Options
8. Rensselaer researcher wins $1.4 million NIH grant to enable faster cancer treatment planning
9. NIH awards $10M to Einstein for diabetes research
10. H1N1, Biodegradable Plastics and Nuclear Physics Highlight Research Areas Undertaken During Houghton College's Summer Research Institute
11. Novel anti-malarial drug candidate found by UT Southwestern researchers
Post Your Comments:
(Date:6/27/2016)... ... June 27, 2016 , ... A revolution is ... emergency ambulance transport experience for the millions of people who require these medical ... the taxi industry through the use of technology. Now, SmartEMS has put forth ...
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A ... 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, where the ... history as home to some of the world’s leading providers of cereal and other ...
(Date:6/26/2016)... ... 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is helping to ... app. The fitness app plans to fix the two major problems leading the fitness industry ... fits all type program , They don’t eliminate all the reasons people quit ...
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica Scruggs ... for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs surgery, ... Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, MD, ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... ... the United States, named Dr. Sesan Ogunleye, as the Medical Director of its new ... the facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ., ... developing innovative inhaled drugs, announced today that it was ... Investments reconstituted its comprehensive set of U.S. and ... "This is an important milestone for Pulmatrix," said Chief ... shareholder awareness of our progress in developing drugs for ...
(Date:6/23/2016)... HILLS, Calif. , June 23, 2016 Any ... the many challenges of the current process. Many of them ... because of the technical difficulties and high laboratory costs involved. ... have to offer it at such a high cost that ... afford it. Dr. Parsa Zadeh , founder ...
(Date:6/23/2016)... June 23, 2016 Capricor ... ), a biotechnology company focused on the discovery, ... that patient enrollment in its ongoing randomized HOPE-Duchenne ... exceeded 50% of its 24-patient target. Capricor expects ... third quarter of 2016, and to report top ...
Breaking Medicine Technology: